Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 11 - 01 save search
Global Ion Exchange Resins Markets, 2021-2026 - Water-Guzzling Industrial Units and Increasing Emphasis on Sustainable Wastewater Treatment Benefit Demand
Published: 2021-11-01 (Crawled : 22:00) - prnewswire.com
BIO | News | $279.73 -0.46% 0.0% 290K
|
Health Technology
|
| O: 0.75%
H: 0.74%
C: -1.39%
treatment ema trial
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
Published: 2021-11-01 (Crawled : 20:00) - biospace.com/
AUPH | $5.01 4.16% 3.99% 1.6M
|
Health Technology
|
| O: -3.26%
H: 4.59%
C: 1.97%
treatment lupkynis results lupus
Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
COCP | $1.495 -1.39% 7.6K
|
Health Technology
|
| O: 3.12%
H: 3.26%
C: 2.72%
covid new drug treatment fda drug
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
THRX | $4.06 0.49% 0
|
|
| O: 1.05%
H: 2.6%
C: -0.98%
new drug fda clearance treatment fda application test gastrointestinal drug clearance
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -4.6%
H: 5.49%
C: 4.83%
treatment
Insights on the Non-Melanoma Skin Cancer Treatment Global Market to 2026 - by Treatment Type, Indication, End-use and Region
Published: 2021-11-01 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.17%
H: 1.58%
C: 0.65%
ICAD | $1.54 -3.15% -3.25% 68K
|
Technology Services
|
| O: 0.0%
H: 0.85%
C: -0.57%
ARAY | $2.135 -3.39% -3.51% 630K
|
Health Technology
|
| O: 0.0%
H: 8.82%
C: 7.01%
treatment skin cancer cancer skin
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
Published: 2021-11-01 (Crawled : 15:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: 0.0%
treatment fda myeloid leukemia leukemia fda approval
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.15%
H: 5.26%
C: 2.92%
treatment cancer antibody license
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
MIRM | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: -0.19%
H: 4.45%
C: 2.4%
treatment syndros lancet
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 0.45%
H: 6.22%
C: 5.78%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: -0.61%
H: 6.17%
C: 6.17%
treatment therapy car-t t-cell
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.